hrp0086rfc5.7 | Management of Disorders of Insulin Secretion | ESPE2016

Early Successful Hematopoietic Cell Transplantation (HSCT) in a Boy with IPEX Syndrome Caused by Novel C.721T>C FOXP3 Mutation

Obermannova Barbora , Formankova Renata , Sumnik Zdenek , Dusatkova Lenka , Pruhova Stepanka , Kayserova Jana , Sedlacek Petr , Lebl Jan

Background: IPEX (OMIM #304790) is a rare and fatal, X-linked immune dysregulatory disorder caused by mutation in transcription factor FOXP3 that result in either quantitative or functional deficiencies of Tregs causing autoimmune disease and allergic inflammation. HSCT is the only curative therapy available for IPEX patients.Objective: Presented boy was born at 38th GW with birth weight 3380 g and birth length 50 cm. Three maternal brothers d...

hrp0086p1-p229 | Diabetes P1 | ESPE2016

Phenotypic Variability of Identical Mutations in the ABCC8 Gene in Two Families

Rozenkova Klara , Zapletalova Jirina , Dusatkova Lenka , Dusatkova Petra , Obermannova Barbora , Pruhova Stepanka , Lebl Jan , Sumnik Zdenek

Background: Mutations in the SUR1 subunit of the KATP channel encoded by the ABCC8 gene can result in diverse phenotypes ranging from Transient Neonatal Diabetes (TNDM) to type 2 diabetes in adulthood. These patients may benefit from sulphonylurea treatment.Objective and hypotheses: To describe the course of diabetes in two families with ABCC8 gene mutations and to assess the effect of sulphonylurea treatment.<p class="ab...

hrp0082p1-d2-74 | Diabetes (1) | ESPE2014

Transient Hyperglycaemia Preceded by Neonatal Hyperinsulinaemic Hypoglycaemia in an Infant with a Novel HNF1A Mutation

Obermannova Barbora , Rozenkova Klara , Dusatkova Petra , Pruhova Stepanka , Sumnik Zdenek , Lebl Jan

Background: The phenotype associated with heterozygous HNF1A gene mutations has recently been extended to include neonatal hyperinsulinaemic hypoglycaemia (HH) in addition to maturity-onset diabetes of the young (HNF1A–MODY).Objective and hypotheses: The baby boy was born at 38th week of gestation; BW 4110 g; BL 53 cm (LGA). The mother had gestational diabetes; her father is treated for diabetes mellitus from the age of 50 years. The boy de...

hrp0094p2-297 | Growth and syndromes (to include Turner syndrome) | ESPE2021

The efficacy and safety of recombinant biosimilar growth hormone treatment in children with GHD and SGA: a Czech retrospective national longitudinal study

Snajderova Marta , Zemkova Daniela , Sumnik Zdenek , Zapletalova Jirina , Pomahacova Renata , Pruhova Stepanka , Cermak Jakub , Sadovska Barbora ,

Objectives: Recombinant growth hormone (rhGH) treatment helps to achieve a final height close to the parental growth potential in children with GH deficiency (GHD) and small for gestational age (SGA). Less is known about efficacy and safety of long term therapy with biosimilar rhGH. The aim of our study is to assess height gain and safety of therapy with biosimilar rhGH (Omnitrope®, Sandoz) in Czech children with GHD and SGA over the first three years of ...

hrp0095rfc10.1 | GH and IGFs | ESPE2022

Clinical and biochemical predictors of Permanent Growth Hormone Deficiency (PGHD) at retesting

Petraroli Maddalena , Messina Giulia , Gnocchi Margherita , Lattanzi Claudia , D'Alvano Tiziana , Argentiero Alberto , Neglia Cosimo , Dora Patianna Viviana , Maria Roberta Esposito Susanna , Elisabeth Street Maria

Background and Aims: Retesting subjects treated with GH throughout childhood at attainment of final height is of importance to identify those having pGHD and needing replacement treatment during transition years and adulthood, and to avoid overtreatment of GH sufficient subjects. This study aimed at evaluating the clinical and biochemical features of patients diagnosed of isolated idiopathic (II) GHD in childhood at retesting to verify the prevalence of perman...

hrp0095p1-532 | Growth and Syndromes | ESPE2022

Cerebral aneurysms and kidney disease in a child with microcephalic osteodysplastic primordial dwarfism type II: novel homozygous mutation in the PCNT gene.

Petraroli Maddalena , Percesepe Antonio , Piane Maria , Gnocchi Margherita , Messina Giulia , Lattanzi Claudia , D'alvano Tiziana , Dora Patianna Viviana , Ormitti Francesca , Maria Roberta Esposito Susanna , Elisabeth Street Maria

MOPD is known to be caused by homozygous loss-of-function mutations in a specific gene, PCNT. Both intra- and interfamilial clinical variability (even for the same variant) have been frequently observed, which makes it difficult to infer a genotype–phenotype correlation. Pericentrin (PCTN) is a structural protein expressed in the centrosome that plays a fundamental role in anchoring protein complexes, regulating mitotic cycle and thus cell proliferation. High levels of m...

hrp0092fc3.2 | Multi-system Endocrine Disorders | ESPE2019

CFTR Loss-of-Function has Effects on microRNAs (miRNAs) that Regulate Genes Involved in Growth, Glucose Metabolism and in Fertility in in vitro Models of Cystic Fibrosis

Cirillo Francesca , Catellani Cecilia , Graziano Sara , Montanini Luisa , Smerieri Arianna , Lazzeroni Pietro , Sartori Chiara , Marmiroli Nelson , Amarri Sergio , Gullì Mariolina , Elisabeth Street Maria

Cystic Fibrosis (CF), is due to CF-transmembrane-conductance-regulator (CFTR) loss-of-function. Significant heterogeneity exists between patients, suggesting potential epigenetic regulation, and comorbidities develop with time. MiRNAs are non-coding RNAs that act as epigenetic regulators. Although many studies have focused on the role for miRNAs in regulating CFTR gene expression, little attention has been given to how CFTR influences their expression and how this affects grow...

hrp0089rfc6.3 | Fat, Metabolism and Obesity | ESPE2018

Effect of the Melanocortin-4 Receptor Agonist, Setmelanotide, on Obesity and Hyperphagia in Individuals Affected by Bardet-Biedl Syndrome

Haws Robert M , Fletty Kristina L , McIntee Thomas J , Green Clayton , Pomeroy Jeremy , Hylan Michelle , Folster Cathy , Davis Elisabeth K , Brady Sheila M , Fiedorek Fred T , Yanovski Jack A

Background: Bardet-Biedl syndrome (BBS) causes early-onset extreme obesity and hyperphagia that is hypothesized to arise from leptin receptor dysfunction. Setmelanotide, a melanocortin-4 receptor (MC4R) peptide agonist, has been shown to induce weight loss in individuals affected by other rare genetic obesity disorders resulting from leptin-melanocortin pathway dysfunction upstream of MC4R.Objective: Report preliminary data on body weight, hunger scores,...

hrp0089rfc8.2 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

High Mobility Group Box 1 (HMGB1) is Increased in Adolescents with Polycystic Ovarian Syndrome (PCOS) and Decreases after Treatment with Myo-Inositol in Combination with α-Lipoic Acid (MYO+ALA)

Cirillo Francesca , Catellani Cecilia , Tridenti Gabriele , Vezzani Cristina , Lazzeroni Pietro , Sartori Chiara , Fulghesu Anna Maria , Losi Simona , Coradazzi Letizia , Amarri Sergio , Street Maria Elisabeth

PCOS treatment in adolescence should aim at improving ovarian function, based on the pathophysiology of this condition. We previously described in cystic fibrosis and then in the PCOS an increase in HMGB1, secondary to reduced cystic fibrosis transmembrane conductance regulator (CFTR) expression in the ovary, associated with insulin resistance and inflammation that both characterize PCOS. Inositols and ALA derivatives are considered a good therapeutic option for their possible...

hrp0089p1-p221 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P1 | ESPE2018

High Mobility Group Box 1 (HMGB1) and Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) are Increased, Insulin Decreased and IL-6 Unchanged in Follicular Fluid (FF) from Polycystic Ovarian Syndrome (PCOS)

Cirillo Francesca , Catellani Cecilia , Lazzeroni Pietro , Sartori Chiara , Morini Daria , Nicoli Alessia , Amarri Sergio , La Sala Giovanni Battista , Street Maria Elisabeth

HMGB1 is a small-protein which reflects both inflammation and insulin-sensitivity. Inflammation and insulin-resistance are features of PCOS. IL-6 is important for ovarian function and can contribute to insulin-resistance. IGFBP-2 behaves like an acute-phase protein and is increased in chronic inflammation. It is also involved in the glucose-metabolism regulation and IGFBP-2 overexpression plays a protective role against insulin-resistance. Insulin functions as a co-gonadotropi...